Suchergebnisse - "Remuzzi, Giuseppe"

PubPharm (40)

1

C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement

enthalten in: Molecular therapy : the journal of the American Society of Gene Therapy | 2024

von Liu, F. | Ryan, S. | Fahnoe, K. | +22

2

Efficacy of GalNAc C3 siRNAs in factor H-deficient mice with C3 glomerulopathy

enthalten in: Molecular immunology | 2024

von Zanchi, C. | Locatelli, M. | Cerullo, D. | +9

3

Liver factor B silencing to cure C3 glomerulopathy : Evidence from a mouse model of complement dysregulation

enthalten in: Molecular immunology | 2023

von Zanchi, C. | Locatelli, M. | Corna, D. | +9

4

Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy

enthalten in: Journal of immunology (Baltimore, Md. : 1950) | 2022

von Zanchi, C. | Locatelli, M. | Cerullo, D. | +10

5

CFH and CFHR structural variants in atypical Hemolytic Uremic Syndrome : Prevalence, genomic characterization and impact on outcome

enthalten in: Frontiers in immunology | 2022

von Piras, R. | Valoti, E. | Alberti, M. | +9

6

Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice

enthalten in: Stem cell research & therapy | 2021

von Casiraghi, F. | Ordonez, P. | Azzollini, N. | +7

7

More about Factor H Autoantibodies in Membranous Nephropathy

enthalten in: The New England journal of medicine | 2019

von Valoti, E. | Noris, M. | Remuzzi, G.

CommentOn: N Engl J Med. 2018 Dec 20;379(25):2479-2481. - PMID 30575481

8

Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy

enthalten in: Pediatric nephrology (Berlin, Germany) | 2019

von Noris, M. | Donadelli, R. | Remuzzi, G.

9

Terminal complement effectors in atypical hemolytic uremic syndrome : C5a, C5b-9, or a bit of both?

enthalten in: Kidney international | 2019

von Noris, M. | Remuzzi, G.

CommentOn: Kidney Int. 2019 Jul;96(1):67-79. - PMID 30910380

10

An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome

enthalten in: American journal of kidney diseases : the official journal of the National Kidney Foundation | 2019

von Galbusera, M. | Noris, M. | Gastoldi, S. | +16